Skip to content
Connect
Stories

The J&J rescue mission starts with a choice

People in this story

The Atlantic, May 2021

Had Johnson & Johnson’s COVID-19 vaccine been the first to get the FDA’s green light, it might have been hailed from the get-go for what it actually is: a scientific and technological marvel. It requires just one injection to confer full immunity—a boon for needlephobes and tough-to-reach populations who can’t easily access a second dose. It’s relatively cheap and has forgiving refrigeration requirements, making it a breeze to ship and store. And clinical trials showed that it’s a knockout at guarding against hospitalization and death, and 66 percent effective at preventing moderate to severe cases of COVID-19, even amid the rise of antibody-dodging coronavirus variants. Johnson & Johnson accomplished all this in less than a year, granting the world a safe and effective vaccine crucial to hastening the pandemic’s eventual end.

That’s not how the J&J story played out.

Continue reading at The Atlantic.

More Stories

An electrical worker installed wiring for heat pumps in a 100-year-old brownstone in Brooklyn, N.Y., on March 22.

Boston, state must act on home heating changes

11.30.2022

Biden and Democrats use ‘assault weapons ban’ to position for 2024

11.29.2022
Howard High School Teachers, 1904

Black Teachers and Liberation: A CBFS Interview

11.30.22
In the News